The revenue split for the partnership is 50% because leronlimab is nearly FDA approved and doesn’t need any further funding or research for the combo indication.

This is in comparison to partnerships for other drugs, which usually take place early in the drug development, where the larger company is taking a risk and wants a bigger piece of the revenue pie.